BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33508568)

  • 1. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
    Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
    Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
    Christopher KL; Elner VM; Demirci H
    Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
    Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
    Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis.
    Sharim J; Tashjian R; Golzy N; Pouratian N
    J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J
    Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cutaneous CD30
    Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
    Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
    [No Abstract]   [Full Text] [Related]  

  • 11. Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports.
    Zanetta C; Filippi M; Moiola L
    Neurol Sci; 2021 May; 42(Suppl 1):9-13. PubMed ID: 33904006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
    Zięba N; Gębka-Kępińska B; Sowa P
    Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
    Petruzzo M; Lanzillo R
    Neurol Sci; 2021 May; 42(Suppl 1):37-39. PubMed ID: 33635428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
    Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis.
    Walker S; Brew B
    J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual adverse dermatologic conditions associated with fingolimod and natalizumab in a patient with relapsing remitting multiple sclerosis.
    Mukharesh L; Maloni H; Maiberger M; Chen W; Wallin M
    Clin Neurol Neurosurg; 2020 Aug; 195():105886. PubMed ID: 32470781
    [No Abstract]   [Full Text] [Related]  

  • 19. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E
    J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701
    [No Abstract]   [Full Text] [Related]  

  • 20. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
    Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C;
    Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.